Epidemiological profile of enterobacter infections in the Clinica Cardiovascular Santa Maria in Medellin, august 2004 – august 2006 Colombia
Article Sidebar
How to Cite
This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.
Downloads
Societal impact
Main Article Content
Abstract
Objective: to describe the clinical and epidemiological characteristics of infections by Enterobacter.
Methods: clinical records of 54 patients who had been hospitalized and had received a confirmed diagnosis of Enterobacter infection were reviewed.
Results: 64.8% of patiens were male, with a mean age of 48. The species which were most commonly isolated included E. cloacae (75%) and E. aerogenes (17%). Mean time for isolation was 9 days after admission to the hospital ward. The samples from which the microorganisms were most commonly isolated were urine (42%) and blood (34%). Urinary tract and bloodstream infection were the most commonly caused by Enterobacter. The infection was considered to be hospital-acquired in 75% of cases. Betalactams antibiotics were the empirical choice at the time of treatment, after the infection diagnosis and before the results of antibiograms the treatment was adjusted in 78% of the patients.
Conclusion: it is important to keep in mind the local resistance profiles when it comes to treatment of this infection in the institution.
Article Details
References
Hoffmann H, Roggenkamp A. Population genetics of the Nomenspecies Enterobacter cloacae. Appl Environ Microbiol. 2003 Sep; 69:5306-5318
Kaye KS, Cosgrove S, Harris A, Eliopoulos GM, Carmeli Y. Risk factors for emergence of resistance to broad-spectrum cephalosporins among Enterobacter spp. Antimicrob Agents Chemother. 2001 Sep; 45 (9): 2628–2630
Thiolas A, Bollet C, La Scola B, Raoult D, Pagès JM. Successive emergence of Enterobacter aerogenes strains resistant to imipenem and colistin in a patient. Antimicrob Agents Chemother. 2005 April; 49(4): 1354–1358
Arpin C, Coze C, Rogues AM, Gachie JP, Bebear C, Quentin C. Epidemiological study of an outbreak due to multidrug-resistant Enterobacter aerogenes in a medical intensive care unit. J Clin Microbiol. 1996 Sep; 34(9): 2163–2169
Pérez D, Máttar S, Mercado M. Alta resistencia de los microorganismos nosocomiales en el Hospital San Jerónimo de Montería. Univ Med. 2003 ;44(3):131- 137
Pumarola A. Enterobacterias Oportunistas. En: Bacteriología Sistemática. Cap 39: 423-429
Vilar-Compte, Sandoval D, Gordillo S, et al. Vigilancia de las infecciones de herida quirúrgica : experiencia de 18 meses en el Instituto Nacional de Cancerología. Salud Pública Méx. 1999; 41 supl.1: S44-S50.
Diaz-Ramos RD, Solorzano-Santos F, Padilla-Barron G, et al. Nosocomial infections. An experience in a high-specialty pediatric hospital. Salud Pública Méx. 1999; 41 suppl.1: S12-S17.
Pitout JDD, Moland ES, Sanders CC, Thomson KS, Fitzsimmons SR. B-Lactamases and detection of bLactam resistance in Enterobacter spp. Antimicrob Agents and Chemother. 1997 Jan; 41 (1): 35–39
Gupta N, Aparna, Choudhary U, Garg N, Arora DR. Enterobacter Bacteremia. JAPI. 2003 Jul; 51: 669- 672
Borer A, Gilad J, Menashe G, Peled N, Riesenberg K, Schlaeffer F. Extended-spectrum B-Lactamaseproducing Enterobacteriaceae strains in communityacquired bacteremia in Southern Israel. Med Sci Monit. 2002; 8(1): CR44-47
Schlesinger J, Navon-Venezia S, Chmelnitsky I, Hammer-Münz O, Leavitt A, Gold HS, Schwaber MJ, Carmeli Y. Extended-Spectrum Beta-Lactamases among Enterobacter Isolates Obtained in Tel Aviv, Israel Antimicrob Agents Chemother. 2005 Mar; 49(3): 1150–1156
González–Mejía EB, Valenzuela E, Mantilla – Anaya JR, Leal – Castro AL, Saavedra – Trujillo CH, Eslava – Schmalbach J, Sierra – Rodríguez P. Resistencia a Cefepime en aislamientos de Enterobacter cloacae provenientes de hospitales de Bogotá, Colombia. Revista de Salud pública. 2006 Jul; 8 (2): 191 -199
Tinoco JC, Pérez-Prado MC, Santillán-Martínez G, et al. Epidemiología de las infecciones nosocomiales en un hospital de segundo nivel. Salud Pública Méx, 1997 Jan-Fev; 39(1): 25-31.
Bennett SN, Mcneil MM, Bland LA, Arduino MJ, Villarino EM, Perrotta DM, et al. Postoperative infections traced to contamination of an intravenous anesthetic, propofol. NEJM. 1995 Jul; 333 (3): 147-154
Lampiris HW, Maddix DS. Uso clínico de antimicrobianos En: Katzung BG, Contreras E, Villalpando J, et al. Farmacología básica y clínica. 8. ed. México: Manual Moderno; 2001. p. 959-975
Gordon RJ, Lowy FD. Bacterial Infections in Drug Users. NEJM. 2005 Nov; 353 (8): 1945-1954
Chambers HF. Antibióticos B lactámicos y otros inhibidores de la pared celular. Cloramfenicol, tetraciclinas, macrólidos, clindamicina y estreptograminas. Aminoglucósidos y espectinomicina. Sulfonamidas, trimetropim y quinolonas. En: Katzung BG, Contreras E, Villalpando J. Farmacología básica y clínica. 8. ed. México: Manual Moderno; 2001. p. 849-902
Arpin C, Dubois V, Coulange L, Andre C, Fischer I, Noury p, et al. Extended-Spectrum B-LactamaseProducin Enterobacteriaceae in community and private health care centers. Antimicrob Agents Chemother. 2003 Nov; 47 (11): 3506–3514
Cheol-In Kang, Sung-Han Kim, Wan Beom Park, KiDeok Lee, Hong-Bin Kim, Eui-Chong Kim, Myoung-don Oh, Kang-Won Choe. Bloodstream Infections caused by antibiotic-resistant gram-negative bacilli: risk factors for mortality and impact of inappropriate initial antimicrobial therapy on outcome. Antimicrob Agents Chemother. 2005 Feb; 49 (2): 760–766
Kollef MH. The Prevention of Ventilator-associated Pneumonia. NEJM. 1999 Feb; 340 (8): 327-634